PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION

International Bureau



INTERNATIONAL

ICATION PUBLISHED UNDER THE PATEN

OPERATION TREATY (PCT)

(51) International Patent Classification 5:

A61B 5/00, G01N 21/31

A1

(11) International Publication Number:

WO 93/06775

(43) International Publication Date:

15 April 1993 (15.04.93)

(21) International Application Number:

PCT/US92/08396

(22) International Filing Date:

1 October 1992 (01.10.92)

(30) Priority data:

771,287

3 October 1991 (03.10.91)

US

(71) Applicant: MEDTRONIC, INC. [US/US]; 7000 Central Avenue N.E., Minneapolis, MN 55432 (US).

(72) Inventors: FOGT, Eric; 9673 Harbor Lane, Maple Grove, MN 55369 (US). LUND, Jeffrey; 20345 Keats Avenue North, Forest Lake, MN 55025 (US). KELLEY, James; 13000 Nightingale Street NW, Coon Rapids, MN 55448 (74) Agents: WILES, Terry, L. et al.; Medtronic, Inc., 7000 Central Avenue, N.E., Minneapolis, MN 55432 (US).

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL,


Published

With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHOD AND APPARATUS FOR DETERMINING OXYGEN SATURATION

(57) Abstract

Blood is passing through a blood circuit where it is exposed to light at red and infrared wavelength. The amount of light reflected is measured at a single distance from the provided infrared light and is used to calculate the hematocrit level. Oxygen saturation is then calculated. In another method, different formulas are used, selected according to the oxygen saturation and/or the hematocrit level. In one embodiment, hematocrit level is determined using measurement of reflected infrared light at the isobestic wavelength of oxy- and deoxyhemoglobin. In another, hematocrit level is determined using measurements of reflected infrared light at two wavelenghts symmetrically disposed about the isobestic wavelength in order to approximate the measurement at this point. The oxygen saturation calculation is based in part on the ratio of the measurement at an infrared wavelength to a separate one



measured at a red wavelength. Particular apparatus including LEDs (20, 22, 24), fiber-optic cables (5) is also disclosed, together with instrumentation (3) for operating the device and effecting the determinations.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
ÄÜ	Australia	GA	Gabon	MW	Malawi
88	Barbados	GB	United Kingdom	NL	Netherlands
88	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG		HU	Hungary	PL	Poland
	Bulgaria	IE.	treland	PT	Portugal
BJ	Benin	ıτ	Italy	RO	Romania
BR	Brazil		*	RU	Russian Federation
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic	SE	Sweden
CC	Congo		of Korea	SK	Slovak Republic
CH	Switzerland	KR	Republic of Korea		· · · · · · · · · · · · · · · · · · ·
CI	Côte d'Ivoire	LI	Licehtenstein	SN	Senegal Soviet Union
CM	Cameroon	LK	Sri Lanka	SU	
cs	Czechoslovakia	ŁU	Luxembourg	TD	Chad
cz	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	ŪΑ	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Vict Nam
ES FI	Finland	*****			
rı	rinkinu				

15

20

25

30

MET AND APPARATUS FOR DETERMINING XYGEN SATURATION BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to fiber-optic sensors for determining oxygen saturation and hematocrit of the blood as it flows through an extracorporeal blood circuit in which it is oxygenated during bypass surgery and the like.

Description of the Prior Art

Fiber-optic sensors for the determination of oxygen saturation (amount of oxygenated hemoglobin), and/or the determination of hematocrit (amount of red blood cells), in the blood in an extracorporeal circuit or otherwise are disclosed in U.S. Patents 4,444,498, 4,447,150, 4,651,741, 4,745,279, 4,776,340 and others. Many such sensors function by providing light to the blood sample via a fiber-optic cable, and measuring the amount of reflected or transmitted light. Light-emitting diodes (LEDs) have been used in these devices to provide radiation at given wavelengths to the sample via the fiberoptic input cables; other fiber-optic cables have transmitted the light reflected by or transmitted through the sample at those wavelengths to photodiodes to produce a current proportionate to the reflected or transmitted light. general, the LEDs alternately, or in series, emit light of one wavelength and then another. See Heinemann, U.S. Patent 4,444,498, Lavallee, U.S. Patent 3,647,299, Goldring, U.S. The calculation of both hematocrit and Patent 4,684,245. oxygen saturation allow calculation of approximately the total oxygen content of the blood.

Hematocrit has been calculated in such devices from a ratio of the amount of light reflected from the blood at two different

10

15

20

25

30

distances from the light source; the isobestic point on the oxy and deoxyhemoglobin reflection curves (about 820 nm) is the wavelength suggested because it is not influenced by the oxygen saturation level. Two detectors are used to receive the reflected light at two different distances from the source, all as disclosed in Moran, U.S. Patent 4,776,340, and Schmitt, et al, An Integrated Circuit-Based Optical Sensor for In Vivo Measurement of Blood Oxygenation, Vol. BME-33, No. 2 IEEE: Transactions on Biomedical Engineering, February 1986.

In Steinke, et al., Reflectance Measurements of Hematocrit and Oxyhemoglobin Saturation, American Journal Physiology 1987, pp H147 to H153 and Schmitt, et al., New Methods for Whole Blood Oximetry 1986, Pergamom Press Ltd., hematocrit is similarly determined, but with two sources at different distances from a single detector. These systems always, however, require three channels to calculate hematocrit, either two source channels and one detector or vice versa. In the Schmitt article, it is further required that the "near" measurement be taken at a higher wavelength than the "far" one.

In Karkar, U.S. Patent 4,745,279, hematocrit in a blood circuit is determined by measuring light diffused by the blood, the light being provided by an LED source adjacent the blood at the isobestic wavelength. A correction is then made for oxygen saturation, and a look-up table used to determine true hematocrit.

In sensors for oxygen saturation, often called oximeters, oxygen saturation has been determined using a number of different equations based on input of light at about 665 nm and about 820 nm, such as:

 $SO_2 = A+B(Ratio_0)$ and $SO_2 = A-B$ (Ratio₀) where

10

15

20

25

 $Ratio_0 = \frac{R_{820}}{R_{665}} \text{and A and B are constants,}$

These equations may depend on the configuration of the particular device. 665 nm is a point of large difference between absorption of deoxyhemoglobin and oxyhemoglobin on the reflection curves; 820 nm or thereabouts is an isobestic point at which the absorption is identical for both compounds.

It was originally thought that the reading at the 820 nm isobestic point in the oxygen saturation calculation would compensate for varying optical density. It was also thought to compensate for varying hematocrit levels because saturation of hemoglobin with oxygen does not influence the amount of reflected light at that point; see Heinemann, U.S. Patent 4,447,150.

However, it has been determined that oxygen saturation results may be inaccurate in certain ranges unless further compensation is made for blood variation. In Shaw, U.S. Patent 4,114,604 and Lubbers, et al., U.S. Patent 3,825,342, a third wavelength is used as well in the measurement of oxyhemoglobin to correct for variability in the blood. In Takatani, et al., A Miniature Hybrid Reflection Type Optical Sensor for Measurement of Hemoglobin Content and Oxygen Saturation of Whole Blood, 35 IEEE: Transactions on Biomedical Engineering 3, March 1988, correction for blood variability

WO 93/06775 PCT/US92/08396

5

10

15

20

was made by adding a constant to the denominator and sometimes also the numerator of Ratio₀, the constant being fixed based on blood characteristics and sensor geometry. In Shaw, et al., U.S. Patent 3,847,483, two non-isobestic wavelengths are used for measuring oxygen saturation using a more complex equation, in order to yield a measurement thought to be independent of blood variation.

In Steinke and Shepherd, Reflectance Measurements of Hematocrit and Oxyhemoglobin Saturation, American Journal Physiology, 1987, pp H147 to H153, the oxygen saturation figure is corrected for hematocrit by calibrating constants used in the oxygen saturation determination according to the hematocrit level. This approach, however, does not allow correction if hematocrit changes, and thus may introduce error into the system.

The latter of the two Schmitt articles, New Methods for Whole Blood Oximetry, 1986, Pergamom Press Ltd. discloses an oxygen saturation measurement made from a device having two identical infrared sources at different distances from the detector, as well as a red light source. Oxygen saturation is measured based on reflected light at these wavelengths using a look-up table which appears to provide an oxygen saturation measurement corrected for variability in hematocrit. However, the Schmitt device requires the separate development and input

15

20

of a particular look-up table not only for each instrument, but for each blood-contacting unit used, a lengthy and time-consuming process for any device which is manufactured on other than a custom basis, or which uses disposable blood-contacting units.

Passafaro, U.S. Patent 4,651,741, discloses corrections for hematocrit made using the following equation: $sO_2 = Ak^2I^2 + BkI + C$, where k is a calibration constant and hematocrit is separately measured in the laboratory. In Passafaro, A, B and C are values based on the hematocrit level, contained in a look-up table, and accessed during the calculation. Since laboratory measurements are not instantaneous, the red blood cell level in the blood in the circuit can change radically without a change in the correction factor, resulting in what might be substantial error in the resulting oxygen saturation measurement.

Moran, et al., U.S. Patent 4,776,340 discloses a catheter system in which hematocrit is calculated based on the ratio of reflected infrared light measured at two different distances from the source. No particular wavelength is suggested; instead it is advised not to try to use the isobestic wavelength for the measurements, but to make a correction in the hematocrit calculation instead. An oxygen saturation

10

15

20

calculation includes a compensation for the hematocrit so calculated.

In Shaw, U.S. Patent 4,114,604, two red wavelengths and one infrared are used in the calculation of oxygen saturation in order to minimize its dependence on blood conditions such as hematocrit. The system described includes electronics for calculating oxygen saturation according to two different formulas, depending on the level of oxygen saturation.

Sperinde, et al., U.S. Patent 4,623,248 discloses a fiberoptic catheter oximeter in which the oxygen saturation level
of the blood is computed by deriving it with a formula which
uses the ratio of one pair of intensity signals when the
oxygen saturation level is relatively low and with a formula
which uses the ratio of another pair of intensity signals when
the oxygen saturation level is high. This, however, while
minimizing the effect of hematocrit on the measurement, does
not correct for it. Further, it always requires the use of
three distinct wavelengths and corresponding LEDs -- two in
the red and one in the infrared.

The above description of art is not intended to constitute an admission that any patent, publication or other information referred to is "prior art" or is enabling with respect to this invention, unless specifically designated as such. In addition, this section should not be construed to mean that a

10

15

20

search was been made or that no other personnent information as defined in 37 C.F.R. § 1.56(a) exists.

Overall, it would be desirable to provide an easily-manufacturable device and a method which provides an oxygen saturation measurement at desired accuracy levels by compensating as necessary for blood variability.

SUMMARY OF THE INVENTION

The present invention is a method and apparatus for determining oxygen saturation in blood passing through a blood circuit which avoids many of the problems associated with prior methods and devices.

In one aspect, the invention is a method of determining oxygen saturation in blood passing through a blood circuit. The method includes the following steps:

providing light to the blood as it passes through the circuit.

receiving light reflected from the blood at a single distance from the provided light,

utilizing the received light to make a representation or approximation of the amount of light reflected from the blood at the isobestic point,

10

15

20

calculating the hematocrit level of the blood passing through the circuit using the representation or approximation made above, and

calculating oxygen saturation in the blood passing through the circuit based on the hematocrit calculation so that the oxygen saturation calculation includes a correction for the hematocrit level calculated as above.

In this aspect, the method of determining oxygen saturation provides an oxygen saturation determination which includes compensation for the hematocrit level of the blood actually concurrently passing through the circuit, without the difficulties of a look-up table or a near/far hematocrit determination.

In this aspect, the light is generally provided at one infrared wavelength and the amount of the infrared light reflected from the blood is measured. Sometimes two infrared wavelengths symmetrically disposed about the isobestic wavelength of oxy- and deoxyhemoglobin are used and the amount of each, reflected from the blood at the same distance from the source, is measured. Generally, red light is also provided to the blood and the amount reflected is measured, so that the oxygen saturation calculation can also be based on the ratio of the amount of infrared-to-red reflected light.

In another aspect, the invention is a sethod of determining oxygen saturation of the blood which includes the following steps:

providing infrared light to the blood,

providing red light to the blood,

measuring the amount of infrared light returned from the blood,

measuring the amount of red light returned from the blood,

10 utilizing the measurement of infrared light to calculate hematocrit level, and

calculating oxygen saturation using the following formula:

15
$$sO_2 = E \cdot Ratio + \frac{F}{Ratio} + \frac{G}{Ratio^2} + \frac{Ratio}{Hct} + \frac{I \cdot Hct}{Hct} + \frac{J}{Hct} + \frac{K}{Hct^2}$$


E, F, G, H, I, J, K are constants, Hct is the percent hematocrit, and Ratio is the ratio of the measurement of infrared-to-red light returned. This approach has been found to provide a particularly accurate oxygen saturation determination.

In another aspect, though, a different formula is used in the invention, as follows:

$$sO_2 = N \cdot Ratio + \frac{O}{Ratio} + \frac{P}{Ratio^2} +$$

10

15



N, O, P, Q, S, and T are constants.

In another aspect, the invention is a method of determining oxygen saturation by using different formulas for the oxygen saturation calculation according to the level of oxygen saturation and/or the level of hematocrit. In one version of this aspect of the invention, the invention includes the following steps:

repeatedly measuring light at a wavelength in the red range reflected from the blood as it passes through the blood circuit,

repeatedly measuring light at a wavelength in the infrared reflected from the blood as it passes through the blood circuit,

repeatedly calculating hematocrit level in the blood as it passes through the blood circuit based on the measurements of infrared light, and

repeatedly determining oxygen saturation in the blood based on the hematocrit level, using more than one formula for the determination according to the level of oxygen saturation. This method of determining oxygen saturation is believed to minimize inaccuracies in the result.

20

15

20

25

In another version of this aspect of the invention, the invention includes the following steps:

repeatedly measuring light at a wavelength in the red range reflected from the blood as it passes through the blood circuit,

repeatedly measuring light at a wavelength in the infrared range reflected from the blood as it passes through the blood circuit,

repeatedly calculating oxygen saturation in the blood based on the measurements above, using a different formula for the determination of oxygen saturation depending on the level of hematocrit in the blood. The oxygen saturation calculation also includes a correction for the hematocrit level of the blood. This approach is believed to minimize inaccuracies in the determination of oxygen saturation.

Specific formulas are provided for the calculations of oxygen saturation and hematocrit in the preferred embodiment of these aspects of the invention. Two preferred formulas for the calculation of hematocrit follow.

$$Hct = A \cdot R_{ISOBESTIC} + B \cdot R_{ISOBESTIC}^{2} + \frac{C}{R_{ISOBESTIC}} + \frac{D}{R_{ISOBESTIC}^{2}}$$

Het = Exp
$$(L \cdot R_{ISOBESTIC} + M/Ln(R_{ISOBESTIC}^2))$$

Also, it should be noted that in one preferred approach, hematocrit is calculated based on a single measurement of

reflected light at about the isobestic wavelength. In another preferred approach, it is calculated using measurements of reflected light at wavelengths symmetrically disposed about the isobestic point. In the latter case, the amount of light reflected at the isobestic point is approximated by measuring the amount reflected at the different infrared wavelengths and approximating or making a representation of the amount reflected at the isobestic point. The following formulas are preferred for making this approximation and are preferably used when light is provided and measured at two infrared wavelengths:

15 or

5

10

20

25

 $R_{\text{ISOBESTIC}} = R_{\text{FIRST INFRARED}} \times R_{\text{SECOND INFRARED}}$

In yet another aspect, the invention includes an apparatus for determining oxygen saturation in blood passing through a blood circuit. The apparatus includes:

means for repeatedly providing light to the blood as it passes through the blood circuit,

means for repeatedly receiving light reflected from the blood at a single distance from the provided light,

means for repeatedly utilizing the received light to approximate the amount of light reflected from the blood at the isobestic wavelength of oxy- and deoxyhemoglobin,

15

20

the blood passing through the blood circuit based on the amount of light reflected from the blood at the isobestic wavelength, and

means for repeatedly calculating oxygen saturation in the blood passing through the blood circuit based on the amount of light reflected from the blood and the calculation of hematocrit so that the oxygen saturation determination includes compensation for the hematocrit level of the blood passing through the circuit, calculated as indicated. Preferably the light is at an infrared wavelength, most preferably at or near the isobestic point.

In this aspect, the apparatus preferably also includes:

means for repeatedly providing light at a red wavelength to the blood,

means for repeatedly measuring the amount of red light reflected from the blood as the blood passes through the blood circuit, and

means for repeatedly measuring the amount of infrared light reflected from the blood as it passes through the blood circuit, where the means for calculating oxygen saturation utilizes the measurements of red and infrared light.

In another aspect, the invention is apparatus for measuring oxygen saturation which includes:

10

15

20

means for repeatedly measuring light at a wavelength in the red range reflected from the blood as it passes through the blood circuit,

means for repeatedly measuring light at a wavelength in the infrared range reflected from the blood as it passes through the blood circuit,

means for repeatedly calculating hematocrit level in the blood as it passes through the blood circuit based on the infrared measurement, and

means for repeatedly determining oxygen saturation in the blood based on the above measurements and the hematocrit calculation, and selecting a different formula for the determination according to the level of oxygen saturation.

Preferably, the apparatus in this aspect includes means for selecting the oxygen saturation formula according to the hematocrit level as well. The hematocrit calculation is usually made using an approximation or representation of the amount of light reflected at the isobestic wavelength, and, in certain embodiments, is made using an actual measurement of the amount of light reflected at the isobestic wavelength.

In yet another aspect, the invention is apparatus for determining oxygen saturation in blood in a blood circuit. The apparatus includes:

10

15

20

25

the red range reflected from the blood as it passes through the blood circuit,

means for repeatedly measuring light at a wavelength in the infrared range reflected from the blood as it passes through the blood circuit, and

means for repeatedly calculating oxygen saturation in the blood based on the measurements, using a different formula for the determination of oxygen saturation according to the level of hematocrit in the blood.

Preferably, the apparatus in this aspect also includes means for repeatedly calculating hematocrit level of the blood as it passes through the circuit and the means for calculating oxygen saturation includes means for correcting the oxygen saturation calculation for the hematocrit level. The means for calculating hematocrit includes a means for approximating the amount of reflected light at the isobestic wavelength of deoxy- and oxyhemoglobin.

In all the above apparati, the means for providing light are preferably light-emitting diodes, the means for measuring the amount of light is a photodiode, and the means for calculating is software. Generally, the blood is passed through a cuvette and the diodes provide and receive light through fiber-optic cables, the emitting cables being equidistant from the receiving cables at the blood or cuvette interface. In

10

15

20

general, the LEDs emit light sequentially and a central processing unit controls the apparatus.

Preferably the wavelength of the infrared light is either at about the isobestic wavelength of oxy- and deoxyhemoglobin, or is at two wavelengths symmetrically disposed about the isobestic wavelength, most preferably at 810 and 830 nm. In the latter case, the software provides one of the abovementioned two formulas for approximating or representing the amount of reflected light at the isobestic point.

The software also provides specific formulas for the calculations of oxygen saturation and hematocrit in the preferred embodiment of these aspects of the invention. Two formulas for the calculation of oxygen saturation and for hematocrit are mentioned above.

In the above aspects, as well as in other aspects, the present invention provides an advantageous method and apparatus for determining oxygen saturation which avoids problems associated with various prior methods and devices.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is an overall illustration of the entire apparatus.

10

15

20

Fig. 2A is a plan view of the end of the fiber-optic cable where it attaches to the cuvette. Fig. 2B is a longitudinal cross-section of the cuvette attached to the cable.

Fig. 3A is a cross section of the bulkhead connector between the cable and the instrument. Fig. 3B is an enlargement of the area where the fiber-optic channels connect and Figs. 3C and 3D are isometric end views of the two parts of the bulkhead connector.

Fig. 4A is a longitudinal cross-section of the cuvette. Fig. 4B is a cross-section of the cuvette taken at lines 4B-4B of Fig. 4A. Fig 4C is a top view of the cuvette and window. Fig. 4D is a cross-section of the calibration cuvette.

Fig. 5A is a cross-section of the lock or latch mechanism attaching the cuvette to the main cable; Figs. 5B and 5C are enlargements. Fig. 5D is a side elevation of the latch mechanism.

Figs. 6A and 6B form a system block diagram for the apparatus.

Figs. 7A and 7B are flow charts, respectively, of the software for the "Calibrate" mode and the "Run" mode.

Figs. 8A and 8B are tables of partitioned equations for the determination of oxygen saturation. Fig. 8C is a flow chart

10

15

20

of software performing the oxygen determinations using the partitioned equations of Fig. 8A, and Fig. 8D is a flow chart of software using the partitioned equations of Fig. 8B.

Fig. 9 is a graph of the reflection curves of deoxygenated and oxygenated hemoglobin showing the isobestic point.

DETAILED DESCRIPTION OF THE SPECIFIC EMBODIMENTS

The present method of determining oxygen saturation is accomplished using the oximetric device described here.

Overall Fiber-optic Sensor System

The preferred embodiment of the system 1 shown in Fig. 1 includes an instrument or electronic module 3 housing LEDs, photodetectors, and hardware and software. Two non-disposable fiber-optic cables 5 and two cuvettes 7a and 7b, which are placed in the blood stream path, are included so that oxygen saturation and hematocrit in blood passing through the cuvettes in the extracorporeal blood circuit can be measured. A printer (not shown) can be attached to the module or housing 3. One cuvette 7a is located in the venous flow path and one, 7b, is located in the arterial flow path, so oxygen saturation and hematocrit of both can be monitored and displayed. The device is physically and operationally identical for both the arterial and venous paths, except where indicated below;

10

15

20

25

therefore only one of the two paths is escribed below unless specific description of the other path is necessary.

II. Fiber-optic Cable

Referring to Figs. 2A and 2B, the preferred cable 5 includes four fiber-optic channels. The fiber-optic channels are formed of polymethyl methacrylate with fluorinated polymer cladding obtained from PolyOptical Products, Inc., Santa Ana, California. One is an emitter channel 10 for transmitting 660 nm radiation from a 660 nm LED (20 in Fig. 6A) to the blood sample; a second is an emitter channel 12 transmitting 810 nm infrared radiation from an 810 nm LED (22 in Fig. 6A) in module 3, to the blood sample; a third is an emitter channel 14 transmitting 830 nm IR radiation from an 830 nm LED (24 in Fig. 6A) in module 3 to the blood sample. A single LED at the true isobestic wavelength (about 820 nm) and a single corresponding channel can be chosen, if available, to avoid the need for both the 810 and 830 nm channels. These emitter channels transmit the radiation through the window of the cuvette 7, discussed below, to the blood sample, illuminating the blood.

The fiber-optic cable 5 also includes a fourth channel 16 for receiving reflected radiation at the input wavelengths, and transmitting it to a signal photodetector 258 (shown in Fig. 6A) in the electronic module. This preferred embodiment measures reflected light, as indicated, but it is within the

10

15

20

scope of the invention to measure transmitted light instead, in the case of an appropriate device.

At the distal end of the cable, the fiber-optic channels are spaced with the emitter channels equidistant from detector channel 16, as shown in Fig. 2A. The preferred fiber-optic channel size for all the emitter channels is .030 inches in diameter, the detector channel is preferably .040 inches in diameter and the emitter channels are preferably located about .047 inches from detector channel 16. For a particular device, the distance of the emitter channels from the detector channel at the blood interface can be optimized using methods known in the art.

III. Bulkhead Connector

The proximal end of the cable is attached to instrument 3 via a bulkhead attachment 30 shown in cross-section in Figs. 1 and 3A, and in 3B and 3C. A round female unit 32 having interior threads 34 and a key 36 is rotatable with respect to the cable. A male unit 38 with threads 31, mounting unit 7 for mounting in housing 3, and key slot 35 is disposed in module 3.

To connect the cable to the module, the male unit is placed within the female unit, key slot to key, and the female unit 32 is rotated to attach the cables to the bulkhead, companion fiber-optic channels not more than .010 inches apart from each

10

15

20

25

other. In enlargement of the connection is shown in Fig. 3B, with a small space 33 between the companion channels.

IV. <u>Cuvette</u>

A cuvette 7a or 7b shown in Figs. 2B, 4A, 4B, and 4C is placed within the extracorporeal blood path for blood flow therethrough during bypass surgery. The blood flows longitudinally through the cuvette through axial cavity 50. The cuvette is molded of polycarbonate for convenient light transmission and is of generally cylindrical shape. Barbed fittings 51 at each end are designed to fit within the tubing of the extracorporeal circuit with a leak-free seal.

V. Latch Connector

When in use, the cuvette is attached to the cable via lock or latch 70 shown in Figs. 2A-B. On cable 5, the lock includes knob 72 rotatable with respect to foot 73 containing the fiber-optic channels. Foot 73 has stops 74 and 76 which limit rotation of knob 72 when they contact extensions 78 and 80. Springs 81 bias foot 73 away from cable 5. Stops 74 and 76 contain key slots or channels 82 and 84, preferably of different sizes. Extensions 78 and 80 together with stops 74 and 76 define an area of rotation of knob 72; the knob can be rotated so that the key slots are located at a position A or a position B as shown. Adjacent the key slots when they are located in position B are lips 86 and 88, each with its own stop 90 and raised lock 92.

Cuvette 7 contains keys 94 and 96, each designed to be received in one of slots 82 or 84; space 95 between them is designed to receive foot 72. Each key defines an aperture 98 and flange 97 which can receive a lip 86 or 88.

The cuvette is attached to the cable by sliding the keys into the appropriate key slots when knob 72 is in position A. Cuvette 7 and foot 73 are then urged toward the cable and the knob rotated so that cuvette flanges 97 pass over locks 92 and reach stops 90 with the knob in position B. Pressure on the cuvette and foot is then released and spring 81 in cooperation with locks 92 firmly hold the channel and cuvette in place with channels 10, 12, 14, 16 abutting window 52 of the cuvette.

System Block Diagram

5

10

15

20

A system block diagram for the entire device is shown in Figs. Bulkhead connector 30 contains three optical 6A and 6B. channels 250, 252, and 254 to conduct LED illumination to the bulkhead. It also contains one optical channel 256 to conduct reflected signal energy to the signal detector 258 and one optical channel 260 to conduct disconnect signal energy to the disconnect detector 262.

Signal detector 258 is connected to the signal detector amplifier 264 that amplifies the signal in a range usable for

10

15

20

the analog-to-digital converter 266. The analog-to-digital converter data is fed to the CPU 270.

Optical channels 250, 252, and 254 are coupled to individual LEDs 20, 22 and 24 of the three wavelengths 660 nm, 810 nm, and 830 nm, respectively. Each LED is energized by its LED driver, shown as one of 274a, b, or c on Fig. 6A. Each LED driver is individually turned on and off by the CPU.

The intensity of each LED is controlled by an individual compensation circuit. Each compensation circuit consists of a compensator detector, one of 276a, b, or c to monitor the LED energy. Each compensator detector is coupled to a compensator detector amplifier, one of 278a, b, or c, which amplifies the signal. Each compensator detector amplifier signal is coupled via a multiplexer, a comparator-integrator and another multiplexer to the appropriate LED driver 274a, b, or c. If the LED energy varies from its set point, this information is fed to the LED driver and the LED driver adjusts the LED energy as necessary to maintain the set point.

In operation, individual LED energies are sequentially triggered to illuminate the sample via cable 5. The reflected energy from the sample is transmitted through the detector channel 16 in cable 5 to the signal detector 258. The signal is amplified by the signal detector amplifier 264, converted to digital data via the analog digital converter 266, and read

10

15

20

by CPU 270. Preferably, the individual has are triggered so that the detector reads first the "ambient" light received along the channel and then reads the reflected light at the LED wavelength. The "ambient" data is subtracted from the reflected data in the software before correction for calibration.

Referring now to Fig. 6B, the CPU 270 is a standard 8-bit micro-controller with RAM 280, ROM 282, a watch dog timer 284, and an asynchronous serial port 286 for attachment to printer 2 in this case. Additional system components are the power supply 288, an LCD display 290, a test switch 292 and an event switch 294 all connected to the CPU.

VII. Software

A. Calibration

When the device is first used, it is calibrated to compensate for variations in the individual system's optical components; by taking measurements under known conditions, normalization factors can be determined for each LED emitter channel and detector channel combinations. Such factors are developed to correct the raw readings at each channel for variations inherent in each system.

Calibration is accomplished in the preferred embodiment using a calibration cuvette 500 shown in Fig. 4D. This is a cuvette designed to be attached to the cable unit in the same fashion

10

15

20

25

as a Endard cuvette. However, it contains a material designed to provide a known amount of reflected light in the device at the selected wavelengths.

The calibration cuvette does not contain a chamber for blood passage; instead, it contains a well 502 to contain reflective material 504. Preferably, for simplicity of manufacture, it otherwise duplicates the standard cuvette as much as possible. Also, it terminates in two bases 506 and 508 which are permanently adhesively attached to the instrument module 3 for convenience of use for each calibration. Material 504 is designed to resemble blood in that the amount of light reflected is similar to that of blood. Since the preferred device is designed to operate maximally with blood giving a signal of about 2.0 to 3.0 volts, the preferred calibration standard gives a signal in this range also.

In an attempt to maximize accuracy of the calibration, the device is preferably calibrated using a calibration standard (material 504) providing a voltage just above the maximum reflected voltage level for blood. Using as high a voltage as possible within the desired level minimizes the effect of errors in the calibration reading on the normalization factors which calibration creates. The maximum voltage read from blood in the preferred embodiment at the 660 nm wavelength is about 2.8 volts while the maximum at the 810 and 830 nm wavelengths is about 2.5 volts. In the preferred embodiment,

10

15

20

thus, the calibration standard reflects as a level equivalent to 3.0 volts on the 660 nm channel and 2.5 volts on the 810 and 830 nm channels.

The material used for the calibration includes a lightscattering agent dispersed at desired levels in a support
medium. The support matrix is substantially non-lightabsorbing at the wavelengths of interest and may be formed of
a number of materials such as silicone elastomers (like Dow
Corning's Silastic MDX 4-4210), urethanes, epoxy, or other
materials. The support matrix is generally chosen for certain
characteristics. Specifically, it should cure to a solid
fairly quickly without allowing the dispersed materials to
settle out. Once cured, its viscosity and other features
should be stable over time. The preferred support matrix is
epoxy which shows limited degradation over time.

A number of light-scattering materials can be used such as titanium dioxide, Tempera paint pigment, silicon carbide, ferric oxide, etc., which can be evenly dispersed in the matrix. These materials should be generally non-varying over time and, if possible, of a uniform particle size.

In some embodiments, dyes may be used to diminish the reflected light at certain wavelengths. These dyes may be included in the support matrix or may be independently

10

15

20

dispersed. Some possible dyes are par 30, a blue pigment dispersion made by Huls Petrarch, Inc., or Thymol blue made by Fisher Chemical Company. The blue dyes will reduce the amount of reflected red light.

The preferred material, specifically, will include about:

59.4% by weight Epoxy resin

35.6% by weight Epoxy hardener

5.0% by weight Titanium dioxide powder

The preferred epoxy is Hexcel Epolite 3310, a 75 Shore D clear epoxy.

The preferred titanium dioxide (or Titanium (IV) Oxide) is a white powder of greater than 99.9% purity in the anatase form.

The mixture is cured in the cavity 502 of calibration cuvette 500 shown in Fig. 4D and is preferably about 1/4 inch thick, or at least thick enough and sufficiently opaque so that ambient light does not enter from the rear.

The calibration constants in the preferred device, 3.0 volts for the 660 nm channel, 2.5 volts on the 810 channel, and 2.5 volts on the 830 nm channel are used to calculate normalization factors as follows:

25



For example, if the voltage read on the 660 channel using the standard is 2.9, the normalization factor for that channel is:

Normalization factor =
$$\frac{\text{Constant}_{660}}{\text{Voltage}} = \frac{3.0}{2.9} = 1.03$$

If, for example, on the other two channels, the voltage on the 810 nm channel during calibration is 2.4 and that on the 830 channel is 2.3, the normalization factor for each will be:

Normalization factor₈₁₀ =
$$\frac{\text{Constant}_{810}}{\text{Voltage}} = \frac{2.5}{2.4} = 1.04$$
and
Normalization factor₈₃₀ = $\frac{\text{Constant}_{830}}{\text{Voltage}} = \frac{2.5}{2.3} = 1.09$

These factors are stored in RAM as the normalization factors for each channel, and thus readings on each channel are separately calibrated and corrected for variability of the system.

A software flow diagram for the calibration process is shown in Fig. 7A.

The CPU first displays "Cal" in the arterial and venous windows 292 to prompt the operator to depress the Test switch

10

15

20

290, waits for the switch to be weld for at least 3 seconds, steps 300, 302 in Fig. 7A. The LED drivers are then directed to energize the LEDs sequentially, step 304.

Data is acquired on the venous and arterial channels at each wavelength as follows. Detector voltages are captured for each wavelength on the venous channel in the hardware capture circuitry described previously. Each captured venous voltage is digitized and stored in RAM in the venous data table, step 304. The same steps are taken for the arterial channel, step 350.

Normalization factors are calculated for each wavelength by the CPU using the acquired data, steps 308, 352. Raw data and the normalization factors are then compared to preset limits for validation, steps 306, 310, 350, 354. If either channel is found to be invalid, the CPU blanks the display. If both channels are invalid, a "Fail" flag is set (and displayed), the "Cal" flag is redisplayed and the procedure must be restarted, steps 314, 358, or problems with the device corrected.

If the venous channel data and normalization factor are found to be valid, an active channel flag is set; the same is done for the arterial channel, step 356. A "Pass" flag is then set and displayed, step 360. If one of the channels is invalid, its display window is blanked.

SUBSTITUTE SHEET

10

15

20

In use, the CPU uses the normalization factors for each channel to correct raw readings before calculating hematocrit and oxygen saturation via software contained in RAM.

B. Run Mode

After calibration, the device operates in the "Run" mode. All variables, flags and registers are initialized for the run mode and normalization factors are included. The run mode is the normal operational mode for the instrument that is active until the device is powered down. An itemization of one run mode cycle after initial testing (step 400, as described above) is then shown in Fig. 7B.

The detector voltages are captured and processed as described in the calibration section above, steps 402, 404, 450, 452. The output is the venous data table which contains values for each wavelength and the arterial data table, which also contains output for each wavelength.

The venous data is processed as follows. If the venous channel is not active, the procedure is exited, 402, and arterial procedure entered. If active, the venous channel data is compared to acceptable limits, 406. If the venous data is not valid, an error message is displayed in the venous display window, 414, and the procedure is exited. If valid, the data (which has already been corrected for ambient signals) is adjusted for VCO non-linearities.

10

15

20

Finally the data for each channel is en normalized, using the normalization factors obtained in the calibration mode. This is done by multiplying the received data by the multiplicative scale factor determined during calibration. For example, in the example shown, the received data on the 660 channel will be multiplied by 1.03, on the 810 channel by 1.04, and on the 830 channel by 1.09. Calculation of hematocrit and then oxygen saturation is then completed as described later using the normalized data.

Venous saturation results produced as described above are then displayed, 410, 412. Arterial channel data is similarly processed, steps 462-462, but venous hematocrit is displayed, 416, if the channel is inactive. Otherwise, arterial saturation and hematocrit are displayed, 460. A printer can be used if desired, see 464-468.

VIII. DETERMINATION OF HEMATOCRIT AND OXYGEN SATURATION

A. Hematocrit

Where an LED is used which actually produces a wavelength at the isobestic point (about 820 nm) for hemoglobin and deoxyhemoglobin, that measurement is used in the calculation of hematocrit. Specifically, using the normalized data, a

SUBSTITUTE SHEET

10

15

20

25

reflectance measurement $R_{\text{ISOBESTIC}}$ OR R_{I} is obtained, as follows for use in the measurement of hematocrit:

$$R_{I} = R_{820}$$

otherwise, LEDs generating wavelengths symmetrically disposed about the isobestic point on the oxy-deoxyhemoglobin curve can be used to generate a representation of the amount of light reflected at the isobestic point. As can be seen on Fig. 9, if an LED generating the exact isobestic wavelength is not available in the device, two LEDs generating wavelengths disposed on either side of the isobestic point can be used. The difference between the two curves at the one wavelength should be equal but opposite to the difference between the two curves at the other wavelength.

For example, in the preferred embodiment, LEDs generating wavelengths of 810 nm and 830 nm can be used, although other wavelengths such as 800 and 840 nm can be used. $R_{\text{ISOBESTIC}}$ or R_{I} can then be represented or approximated as follows:

$$R_{I} = \frac{R_{FIRST INFRARED} + R_{SECOND INFRARED}}{2}$$

or

R_I = R_{FIRST INFRARED} × R_{SECOND INFRARED}

In the preferred embodiment, then
$$R_{I} = \left(\frac{R_{810} + R_{830}}{2}\right) \text{ or } \left(R_{810} \times R_{830}\right),$$

¹It should be noted that LEDs used should be screened to determine <u>actual</u> wavelengths emitted, since the actual may not be the same as the labeled wavelength.

10

15

20

This equation, including constants A, B, C and D, was empirically derived by comparing R_l values and their associated known hematocrit values, and is believed to provide very accurate measurements. In the preferred embodiment, the constants have been found to be as follows, using the first equation for R_l provided above. Where the second equation for R_l is used, a different set of constants must be generated, as is the case when R_l is measured directly, using a wavelength at about the actual isobestic point on the curve.

A = 19.670148

B = 6.833192

C = 9.833347

D = 0.8262

Under abnormal physiological conditions (such as very unusual flow rates, pH, etc.), it may be desirable to use a modified equation which is believed to be more accurate under such conditions, e.g.:

$$Hct = Exp \left(L \cdot R_1 + \frac{M}{Ln(R_1^2)} \right)$$

This equation was developed by including such abnormal test data while generating the hematocrit calculation formula. L and M are constants generated for the device.

B. Oxygen Saturation

Oxygen saturation is determined using a Ratioo where:

$$R_0 = R_{INFRARED} \times R_{RED}$$

Specifically, here:

$$Ratio_{0} = \frac{R_{830}}{R_{660}}$$

If an actual isobestic wavelength is used instead of the 830 $\,$ nm LED, then

$$Ratio_{0} = \frac{R_{ISOBESTIC}}{R_{660}}$$

Oxygen saturation is then calculated as follows, where Hct is the hematocrit value determined above:

E through K are constants determined for the device before manufacture by comparing data from numerous such test devices to actual oxygen saturation figures.

Specifically, in the device shown,

E = 3.462727

F = 36.690131

G = 7.060379

H = 500.693864

I = 0.570215

1425.89362

K = 7708.556902

Different constants will be generated where $R_{\text{ISOBESTIC}}$ is used rather than R_{830} .

5 This approach is believed to provide particularly accurate oxygen saturation data. Not only is the oxygen saturation data corrected for hematocrit variations, but it is also corrected for hematocrit which is measured essentially instantaneously. Furthermore, hematocrit is believed to be calculated very accurately via such actual or approximated reflectance at the isobestic point. Thus, variations in, and errors in the calculation of, the hematocrit level during a bypass procedure does not result in erroneous saturation readings.

Again, to avoid error under abnormal physiological conditions in some embodiments, the following modified calculation of oxygen saturation can be used:

 $sO_2 = N \cdot Ratio_0 + O/Ratio_0 + P/(Ratio_0^2) +$

Q.Ratio_o/Hct + S.Hct + T.Ln(Hct)

Determining sO_2 in this fashion is believed to reduce sO_2 error, particularly under abnormal conditions. N through T are constants determined for the individual device.

10

15

20

25

It was found possible to optimize the carculation of oxygen saturation by partitioning the response curves of the device and including abnormal values. Partitioning was done by both sO_2 level and by hematocrit level to give sixteen formulas, four sO_2 ranges in each of four hematocrit ranges. Partitioning only by hematocrit level provided four formulas. Fig. 8A contains sixteen particular equations found optimum for the calculation of sO_2 in the preferred embodiment, partitioning by both Hct and sO_2 , when used in connection with bovine blood; Fig. 8B lists the four particular equations found optimum when hematocrit levels alone were used. Levels of hematocrit and sO_2 as referred to in the Figures are as follows:

High Hct (level 1) = 33 - 40%

Medium high Hct (level 2) = 26 - 33%

Medium low Hct (level 3) = 21 - 26%

Low Hct (level 4) = 14 - 21%

High sO_2 = 90 - 100%

Medium high sO_2 = 70 - 90%

Medium low sO_2 = 50 - 70%

Low so2

Software for incorporating the formulas of Figs. 8A and 8B in the device can be prepared by one of ordinary skill in the art. Sample flow charts, however, for such software are provided in Figs. 8C and 8D. It should be noted that in actually utilizing these equations, Ratio₀ is used as an estimate of so₂ rather than the fully-calculated so₂ value.

= 30 - 50%

10

15

20

Also, the figures (and the claims Ratio is sometimes referred to as "Ratio" or "Rat."

This approach is believed to further improve the accuracy of the sO_2 determination, as indicated by a reduction in the standard deviation of the bias with the 4-block partition and a further reduction with the 16-block approach. (Data shows the reduction to be from 2.2 to 1.2 to 1.0.)

IX. Use of the Device

The device is first assembled before use, the second cable unit attached to the instrument using the bulkhead attachment and the cuvettes placed in what will be the extracorporeal circuit after it is primed. The cables are attached to the cuvettes using the latches. The device is then calibrated using the calibration cell provided, before priming.

Once the system has been primed and is running, the device can be used to measure hematocrit and oxygen saturation. Using the equations set forth above, the device displays hematocrit readings and oxygen saturation readings. A printer can be activated to print readings if desired. Once the surgery is completed, the cuvette is removed from the circuit and disposed of, and the device readied for another use, with another cuvette, following the procedures described above.

It will be understood that the above description and the illustrations are provided by way of example only, that alternate versions, equivalents, and examples will be apparent to those skilled in the art, and will be within the scope of the invention which is defined by the appended claims. For example, transmitted rather than reflected light can be measured with certain devices.

15

20

25

WHAT IS CLAIMED IS:

- 1. A method of determining oxygen saturation in blood passing through a blood circuit comprising the following steps:
- a) providing light to the blood as it passes through the blood circuit;
- b) receiving light reflected from the blood at a given distance from the provided light;
- c) utilizing the received light to make an approximation of the amount of light reflected from the blood at the isobestic wavelength of oxy- and deoxyhemoglobin;
- d) calculating the hematocrit level of the blood passing through the blood circuit using the determination of step c); and e) calculating oxygen saturation in the blood passing through the blood circuit based on the amount of light reflected from the blood and the calculation made in step d) so that the oxygen saturation determination includes a correction for the hematocrit level of the blood passing through the circuit, calculated according to the amount of light reflected at the isobestic wavelength of oxy- and deoxyhemoglobin.
- 2. A method of determining oxygen saturation in blood in a blood circuit according to claim 1 further comprising the following steps:
- f) repeatedly providing light to the blood at a wavelength in the red range;

- g) repeatedly providing the light of step a) at a wavelength in the infrared range;
- h) repeatedly measuring the amount of the red light reflected from blood, as the blood passes through the blood circuit;
- i) repeatedly measuring the infrared light reflected from blood as the blood passes through the blood circuit; and
- j) calculating oxygen saturation based on the results of steps e) and i).

5

3. A method according to claim 2 and wherein the wavelength of the infrared radiation is at about the isobestic point of oxy- and deoxyhemoglobin so that the measurement of step i) can be used as the approximation of step c).

15

4. A method according to claim 2 and further including the steps of k) repeatedly providing light at a second infrared wavelength to the blood and l) repeatedly measuring the amount of the second infrared wavelength reflected from the blood at a single distance from the light provided, where the two infrared wavelengths are symmetrically disposed on different sides of the isobestic point.

20

25

5. A method according to claim 4 and wherein the determination of oxygen saturation includes the step of calculating the ratio of the measurement of step i) to the measurement of step h).

10

15

20

- 6. A method according to claim 2 and wherein different formulas are used in the determination of oxygen saturation according to the hematocrit level.
- 7. A method according to claim 2 and wherein different formulas are used for the determination of oxygen saturation according to the oxygen saturation level.
- 8. A method of determining oxygen saturation of blood in a blood circuit comprising the following steps:
- a) repeatedly measuring light at a wavelength in the red range of the blood as it passes through the blood circuit;
- b) repeatedly measuring light at a wavelength in the infrared range reflected from the blood as it passes through the blood circuit;
- c) repeatedly calculating hematocrit level in the blood as it passes through the blood circuit based on the measurements of step b);
- d) repeatedly determining oxygen saturation in the blood based on the measurements of steps a), b) and c), using more than one different formula for the determination, depending on the level of oxygen saturation.
- 9. A method according to claim 8 further comprising the following steps
 - e) repeatedly providing red light to the blood;
 - f) repeatedly providing infrared light to the blood

10

15

20

and wherein the formula is selected according to the hematocrit level.

- 10. A method according to claim 9 and wherein the wavelength in the infrared range is at the isobestic point on the reflection curves of deoxy- and oxyhemoglobin, so that the measurement of step b is used as the approximation of the amount of light reflected at the isobestic point.
- 11. A method according to claim 9 and further including the steps of repeatedly providing light at a second infrared wavelength to the blood and repeatedly measuring the amount of the second infrared wavelength reflected from the blood, where the two infrared wavelengths are symmetrically disposed on different sides of the isobestic point.
- 12. A method according to claim 9 and wherein the determination of oxygen saturation includes the step of calculating the ratio of the measurement of step b) to the measurement of step a).
 - 13. A method of determining oxygen saturation in blood in a blood circuit comprising the following steps:
 - a) repeatedly measuring light at a wavelength in the red range reflected from the blood as it passes through the blood circuit;

10

15

20

b) repeatedly measuring light at a wavelength in the infrared range reflected from the blood as it passes through the blood circuit;

- c) repeatedly calculating oxygen saturation in the blood based on the measurements taken in steps a) and b), using a different formula for the determination of oxygen saturation depending on the level of hematocrit in the blood.
- 14. A method according to claim 13 and further including a step d) of repeatedly calculating hematocrit level in the blood as it passes through the blood circuit e) of repeatedly providing red light to the blood, and f) of repeatedly providing infrared light to the blood, and wherein the calculation of oxygen saturation is based on the measurements taken in steps a) and, b), and the calculation of step d), so that the oxygen saturation calculation includes a correction for the hematocrit level of the blood passing through the circuit.
- 15. A method according to claim 14 and wherein the calculation of hematocrit is based on the measurement of step b) only.
- 16. A method according to claim 15 and wherein hematocrit is determined using a calculation based on an approximation of the amount of reflected light at the isobestic point on the reflection curves of deoxy and oxyhemoglobin.

PCT/US92/08396

5

10

15

20

25

17. A method according to claim 16 and further including the steps g) of repeatedly providing light at a second infrared wavelength to the blood and h) repeatedly measuring the amount of the second infrared wavelength reflected from the blood, where the two infrared wavelengths are symmetrically disposed on different sides of the isobestic point.

18. A method according to claim 4, 11, and 17 and wherein the approximation of the amount of light reflected at the isobestic point is made according to the following formula, where R represents the amount of reflected light at the specified wavelength:

19. A method according to claim 4, 11, and 17 and wherein the approximation of the amount of light reflected at the isobestic point is made according to the following formula, where R represents the amount of reflected light at the specified wavelength:

R_{ISOBESTIC} = R_{FIRST INFRARED} X R_{SECOND INFRARED}

20. A method according to claim 2, 9 or 13 and wherein hematocrit is determined using the following formula, where A, B, C, and D are constants and $R_{\text{ISOBESTIC}}$ represents the amount of light reflected from the blood at the isobestic point on the reflection curve of oxy- and deoxyhemoglobin:

10

15

Het =
$$A \cdot R_{ISOBESTIC} + B \cdot R_{ISOBESTIC}^2 + \frac{D}{R_{ISOBESTIC}}$$

21. A method according to claim 2, 9 or 13 and wherein hematocrit is determined using the following formula, where L and M are constants and $R_{\text{ISOBESTIC}}$ represents the amount of light reflected from the blood at the isobestic wavelength:

$$Hct = Exp \left(L \cdot R_{ISOBESTIC} + \frac{M}{Ln \left(R_{ISOBESTIC}^{2} \right)} \right)$$

22. A method according to claims 2, 9 or 15 and wherein the wavelength of the red radiation is at about 660 nm.

23. A method according to claims 4, 11, or 17 and wherein the first infrared wavelength is about 810 nm and the second infrared wavelength is about 830 nm.

24. A method according to claim 15 and wherein the determination of oxygen saturation includes the step of calculating the ratio of the measurement of step b) to the measurement of step a).

25. A method according to claim 24 and wherein different formulas are used in the calculation of oxygen saturation according to the hematocrit level.

26. A method according to claim 9 or R^2 and wherein for a given hematocrit range, the oxygen saturation formula is selected according to the level of oxygen saturation from the following group of formulas, where A_1 , B_1 , C_1 , D_1 , A_2 , B_2 , C_2 , A_3 , B_3 , C_3 , D_3 , A_4 , B_4 , C_4 and D_4 are constants, and Ratio is the ratio of the infrared measurement to the red measurement:

$$A_{1} \cdot \text{Ratio} + \frac{B_{1}}{\text{Ratio}} + C_{1} \cdot (\text{Ratio}^{2}) + D_{1} \cdot \text{Ln}(\text{Hct})$$

$$A_{3} \cdot \text{Ratio} + \frac{B_{3}}{\text{Ratio}} + \frac{C_{3}}{\text{Ratio}^{2}} + D_{3} \cdot \text{Ln}(\text{Hct})$$

$$\frac{A_{2}}{\text{Ratio}} + \frac{B_{2}}{\text{Ratio}^{2}} + C_{2} \cdot \text{Ln}(\text{Hct})$$
and
$$A_{4} \cdot \text{Ratio} + \frac{B_{4}}{\text{Ratio}_{0}} + \frac{C_{4}}{\text{Ratio}^{2}} + D_{4} \cdot \text{Ln}(\text{Hct})$$

27. A method according to claim 9 or 16 and wherein for a given hematocrit range, the oxygen saturation formula is selected according to the level of oxygen saturation from the following group of formulas, where A₅, B₅, C₅, D₅, A₆, B₆, C₆, D₆, A₇, B₇, C₇, D₇, A₈, B₈, C₈, and D₈ are constants, and Ratio is the ratio of the infrared measurement to the red measurement:

$$A_{5} \cdot \text{Ratio} + \frac{B_{5}}{\text{Ratio}} + \frac{C_{5}}{\text{Ratio}^{2}} + D_{5} \cdot \text{Ln}(\text{Hct})$$

$$A_{7} \cdot \text{Ratio} + \frac{B_{7}}{\text{Ratio}} + C_{7} \cdot \text{Ln}(\text{Hct}) + D_{7} \cdot \frac{\text{Hct}}{\text{Ratio}}$$

$$A_{6} \cdot \text{Ratio} + \frac{B_{6}}{\text{Ratio}} + \frac{C_{6}}{\text{Ratio}^{2}} + \frac{D_{6}}{\text{Hct}}$$
35
and
$$A_{8} \cdot \text{Ratio} + \frac{B_{8}}{\text{Ratio}} + \frac{C_{8}}{\text{Ratio}^{2}} + D_{8} \cdot \text{Ln}(\text{Hct})$$

25

28. A method according to claim 9 or 16 and wherein for a given hematocrit range, the oxygen saturation formula is selected according to the level of oxygen saturation from the following group of formulas, where A_9 , B_9 , C_9 , D_9 , A_{10} , B_{10} , C_{10} , D_{10} , E_{10} , A_{11} , B_{11} , C_{11} , D_{11} , A_{12} , B_{12} , C_{12} , and D_{12} are constants, and Ratio is the ratio of the infrared measurement to the red measurement:

10
$$A_{9} \cdot \text{Ratio} + \frac{B_{9}}{\text{Ratio}} + \frac{C_{9}}{\text{Ratio}^{2}} + D_{9} \cdot \frac{\text{Ratio}}{\text{Hct}}$$

$$A_{11} \cdot \text{Ratio} + \frac{B_{11}}{\text{Ratio}} + C_{11} \cdot \text{Ln}(\text{Hct}) + D_{11} \cdot \frac{\text{Hct}}{\text{Ratio}}$$
15
$$A_{10} \cdot \text{Ratio} + \frac{B_{10}}{\text{Ratio}} + \frac{C_{10}}{\text{Ratio}^{2}} + D_{10} \cdot \text{Ln}(\text{Hct}) + E_{10} \cdot \frac{\text{Hct}}{\text{Ratio}}$$
and
$$A_{12} \cdot \text{Ratio} + \frac{B_{12}}{\text{Ratio}} + \frac{C_{12}}{\text{Ratio}^{2}} + D_{12} \cdot \text{Ln}(\text{Hct})$$

29. A method according to claim 9 or 16 and wherein for a given hematocrit range, the oxygen saturation formula is selected according to the level of oxygen saturation from the following group of formulas, where A_{13} , B_{13} , C_{13} , D_{13} , A_{14} , B_{14} , C_{14} , D_{14} , A_{15} , B_{15} , C_{15} , D_{15} , A_{16} , B_{16} , and C_{16} are constants, and Ratio is the ratio of the infrared measurement to the red measurement:

$$A_{13} \cdot \text{Ratio} + \frac{B_{13}}{\text{Ratio}} + \frac{C_{13}}{\text{Ratio}^{2}} + D_{13} \cdot \frac{\text{Ratio}}{\text{Hct}}$$

$$A_{15} \cdot \text{Ratio} + \frac{B_{15}}{\text{Ratio}} + C_{15} \cdot \text{Ln(Hct)} + D_{15} \cdot \frac{\text{Hct}}{\text{Ratio}}$$

$$A_{14} \cdot \text{Ratio} + \frac{B_{14}}{\text{Ratio}} + \frac{C_{14}}{\text{Ratio}^{2}} + \frac{D_{14}}{\text{Hct}}$$

and

$$\frac{A_{16}}{\text{Ratio}} + \frac{B_{16}}{\text{Ratio}^2} + C_{16} \cdot \text{Ln(Hct)}$$

30. A method according to claim 9 or 16 and wherein for a given oxygen saturation range, the oxygen saturation formula is selected according to the level of hematocrit, where A₁, B₁, C₁, D₁, A₅, B₅, C₅, D₅, A₉, B₉, C₉, D₉, A₁₃, B₁₃, C₁₃ and D₁₃ are constants and Ratio is the ratio of the infrared measurement to the red measurement:

15
$$A_{1} \cdot \text{Ratio} + \frac{B_{1}}{\text{Ratio}} + C_{1} \cdot (\text{Ratio}^{2}) + D_{1} \cdot \text{Ln}(\text{Hct})$$

$$A_{5} \cdot \text{Ratio} + \frac{B_{5}}{\text{Ratio}} + \frac{C_{5}}{\text{Ratio}^{2}} + D_{5} \cdot \text{Ln}(\text{Hct})$$

$$A_{9} \cdot \text{Ratio} + \frac{B_{9}}{\text{Ratio}} + \frac{C_{9}}{\text{Ratio}^{2}} + D_{9} \cdot \frac{\text{Ratio}}{\text{Hct}}$$
20
$$A_{13} \cdot \text{Ratio} + \frac{B_{13}}{\text{Ratio}} + \frac{C_{13}}{\text{Ratio}^{2}} + D_{13} \cdot \frac{\text{Ratio}}{\text{Hct}}$$

31. A method according to claim 9 or 16 and wherein for a given oxygen saturation range, the oxygen saturation formula is selected according to the level of hematocrit, where A₃, B₃, C₃, D₃, A₇, B₇, C₇, D₇, A₁₁, B₁₁, C₁₁, D₁₁, A₁₅, B₁₅, C₁₅ and D₁₅ are constants and Ratio is the ratio of the infrared measurement to the red measurement:

30
$$A_3 \cdot \text{Ratio} + \frac{B_3}{\text{Ratio}} + \frac{C_3}{\text{Ratio}^2} + D_3 \cdot \text{Ln(Hct)}$$

$$A_7 \cdot \text{Ratio} + \frac{B_7}{\text{Ratio}} + C_7 \cdot \text{Ln(Hct)} + D_7 \cdot \frac{\text{Hct}}{\text{Ratio}}$$

10

30

$$A_{11} \cdot \text{Ratio} + \frac{B_{11}}{\text{Ratio}} + C_{11} \cdot \text{Ln}(\text{Hct}) + D_{11} \cdot \frac{\text{Hct}}{\text{Ratio}}$$
and
$$A_{15} \cdot \text{Ratio} + \frac{B_{15}}{\text{Ratio}} + C_{15} \cdot \text{Ln}(\text{Hct}) + D_{15} \cdot \frac{\text{Hct}}{\text{Ratio}}$$

32. A method according to claim 9 or 16 and wherein for a given oxygen saturation range, the oxygen saturation formula is selected according to the level of hematocrit, where A_2 , B_2 , C_2 , A_6 , B_6 , C_6 , D_6 , A_{10} , B_{10} , C_{10} , D_{10} , A_{16} , B_{16} , and C_{16} are constants and Ratio is the ratio of the infrared measurement to the red measurement:

15
$$\frac{A_{2}}{Ratio} + \frac{B_{2}}{Ratio^{2}} + C_{2} \cdot Ln(Hct)$$

$$A_{6} \cdot Ratio + \frac{B_{6}}{Ratio} + \frac{C_{6}}{Ratio^{2}} + \frac{D_{6}}{Hct}$$
20
$$A_{10} \cdot Ratio + \frac{B_{10}}{Ratio} + \frac{C_{10}}{Ratio^{2}} + D_{10} \cdot Ln(Hct) + E_{10} \cdot \frac{Hct}{Ratio}$$
25
$$\frac{A_{16}}{Ratio} + \frac{B_{16}}{Ratio^{2}} + C_{16} \cdot Ln(Hct)$$

33. A method according to claim 9 or 16 and wherein for a given oxygen saturation range, the oxygen saturation formula is selected according to the level of hematocrit, where A_4 , B_4 , C_4 , D_4 , A_8 , B_8 , C_8 , D_8 , A_{12} , B_{12} , C_{12} , D_{12} , A_{14} , B_{14} , C_{16} and D_{16} are constants and Ratio is the ratio of the infrared measurement to the red measurement:

$$A_4 \cdot \text{Ratio} + \frac{B_4}{\text{Ratio}_0} + \frac{C_4}{\text{Ratio}^2} + D_4 \cdot \text{Ln}(\text{Hct})$$

PCT/US92/08396 WO 93/06775 50

$$A_8 \cdot \text{Ratio} + \frac{B_8}{\text{Ratio}} + \frac{C_8}{\text{Ratio}^2} + D_8 \cdot \text{Ln(Hct)}$$

$$A_{12}$$
·Ratio + $\frac{B_{12}}{Ratio}$ + $\frac{C_{12}}{Ratio^2}$ + D_{12} · Ln(Hct)

and

5

10

15

20

25

30

 A_{14} Ratio + $\frac{B_{14}}{Ratio}$ + $\frac{C_{14}}{Ratio^2}$ + $\frac{D_{14}}{Hct}$

A method of determining oxygen saturation of the blood comprising the following steps:

providing infrared light to the blood;

providing red light to the blood;

measuring the amount of infrared light returned from the blood;

measuring the amount of red light returned from the blood;

utilizing the measurement of infrared light to calculate hematocrit; and

calculating oxygen saturation using the following formula, where E, F, G, H, I, J, and K are constants, R is the ratio of the measurement of infrared to red light returned, and Hct is the percent hematocrit:

A method of determining oxygen saturation to the blood comprising the following steps:

providing infrared light to the blood;

providing red light to the blood;

10

15

20

25

meadring the amount of infrared light returned from the blood;

measuring the amount of red light returned from the blood;

utilizing the measurement of infrared light to calculate hematocrit; and

calculating oxygen saturation using the following formula, where N, O, P, Q, S, and T are constants, Ratio is the ratio of the measurement of infrared to red light returned, and Hct is the percent hematocrit:

36. Apparatus for determining oxygen saturation in blood passing through a blood circuit comprising:

means for repeatedly providing light to the blood as it passes through the blood circuit;

means for repeatedly receiving light reflected from the blood at a single distance from the provided light;

means for repeatedly utilizing the received light to approximate the amount of light reflected from the blood at the isobestic wavelength of oxy- and deoxyhemoglobin;

means for repeatedly calculating the hematocrit level of the blood passing through the blood circuit based on the amount of light reflected from the blood at the isobestic wavelength; and means for repeatedly calculating oxygen saturation in the blood passing through the blood circuit based on the amount of light reflected from the blood and the calculation of hematocrit so that the oxygen saturation determination includes a correction for the hematocrit level of the blood passing through the circuit, calculated according to the amount of light reflected at the isobestic wavelength of oxyand deoxyhemoglobin.

10

5

37. Apparatus according to claim-36 and further comprising:
 means for repeatedly providing light at a red wavelength
to the blood, wherein said first means for providing light
provides light at an infrared wavelength;

means for repeatedly measuring the amount of red light reflected from the blood as the blood passes through the blood circuit; and

15

means for repeatedly measuring the amount of infrared light reflected from the blood as it passes through the blood circuit

20

wherein the means for calculating oxygen saturation utilizes the measurements of red and infrared light.

38. Apparatus according to claim 37 and wherein the means for repeatedly providing light are light-emitting diodes, the means for measuring the amount of light is a photodiode and the means for calculating is comprised of software.

39. Applicatus according to claim 38 and energin the blood is passed through a cuvette, the light-emitting diodes provide light to the blood through fiber-optic cables, and the photodiode receives light through a fiber-optic cable.

5

40. Apparatus according to claim 38 and further including an LED emitting light at a second infrared wavelength to the blood, where the two infrared wavelengths are symmetrically disposed on different sides of the isobestic point.

·..10

41. Apparatus according to claim 37 and including software to calculate oxygen saturation level according to the following formula, where E, F, G, H, I, J, and K are constants, Hct is percent hematocrit, and ratio is the ratio of reflected light at the infrared range to that at the red range:

15

20

42. Apparatus according to claim 37 and including software to calculate oxygen saturation level according to the following formula, where N, O, P, Q, S, and T are constants, Hct is percent hematocrit, and Ratio is the ratio of reflected light at the infrared range to that at the red range:

sO₂ = N·Ratio + O/Ratio + P/(Ratio²) +
Q·Ratio/Hct + S·Hct + T·Ln(Hct)

10

15

20

- 43. Apparatus according to claim 38 and wherein the software provides more than one formula for the determination of oxygen saturation according to the level of hematocrit.
- 44. Apparatus according to claim 38 and wherein the software provides more than one formula for the determination of oxygen saturation according to the oxygen saturation level.
- 45. Apparatus for determining oxygen saturation of blood in a blood circuit comprising:

means for repeatedly measuring light at a wavelength in the red range, of the blood as it passes through the blood circuit;

means for repeatedly measuring reflected light at a wavelength in the infrared range reflected from the blood as it passes through the blood circuit;

means for repeatedly calculating hematocrit level in the blood as it passes through the blood circuit based on the measurements of step b); and

means for repeatedly determining oxygen saturation in the blood based on the measurements, and the calculation of hematocrit, and selecting a different formula for the determination according to the level of oxygen saturation.

46. Apparatus according to claim 45 and wherein the means for determining oxygen saturation includes means for selecting a different formula according to the level of hematocrit.

47. A ethod according to claim 9 when the hematocrit level is calculated based on an approximation of the amount of light reflected at the isobestic wavelength on the reflection curve of oxy- and deoxyhemoglobin.

5

48. Apparatus according to claim 46 and wherein the means for calculating hematocrit includes means for calculating using an approximation of the amount of light reflected at the isobestic wavelength of oxy- and deoxyhemoglobin.

10

49. Apparatus according to claim 48 and wherein the wavelength in the infrared range is at the isobestic wavelength.

15

50. Apparatus according to claim 46 and wherein the means for calculating oxygen saturation includes means for calculating the ratio of the measurement of infrared light to the measurement of red light.

51. Apparatus according to claim 48 and wherein the means for repeatedly providing light are light-emitting diodes, the means for measuring the amount of light is a photodiode, and the means for calculating is comprised of software.

20

52. Apparatus according to claim 51 and wherein the blood is passed through a cuvette, the light-emitting diodes provide

10

15

20

light to the blood through fiber-optic cables, and the photodiode receives light through a fiber-optic cable.

53. Apparatus according to claim 51 and further including an LED emitting light at a second infrared wavelength to the blood, where the two infrared wavelengths are symmetrically disposed on different sides of the isobestic wavelength.

54. Apparatus for determining oxygen saturation in blood in a blood circuit comprising:

means for repeatedly measuring light at a wavelength in the red range reflected from the blood as it passes through the blood circuit;

means for repeatedly measuring light at a wavelength in the infrared range reflected from the blood as it passes through the blood circuit; and

means for repeatedly calculating oxygen saturation in the blood based on the measurements, using a different formula for the determination of oxygen saturation according to the level of hematocrit in the blood.

55. Apparatus according to claim 54 and further comprising means for repeatedly calculating hematocrit level of the blood as it passes through the blood circuit and wherein the means for calculating oxygen saturation includes means for correcting the oxygen saturation calculation for the hematocrit level.

15

20

- 56. Apparatus according to claim 55 further comprising means for providing red light to the blood and means for providing infrared light to the blood, and wherein the means for calculating hematocrit includes a means for approximating the amount of reflected light at the isobestic wavelength on the reflection curves of deoxy- and oxyhemoglobin.
- 57. Apparatus according to claim 55 and wherein the means for repeatedly providing light are light-emitting diodes, the means for measuring the amount of light is a photodiode, and the means for calculating is comprised of software.
- 58. Apparatus according to claim 55 and wherein the blood is passed through a cuvette, the light-emitting diodes provide light to the blood through fiber-optic cables, and the photodiode receives light through a fiber-optic cable.
- 59. Apparatus according to claim 58 and further comprising a light-emitting diode for providing light at a second infrared wavelength to the blood and means for repeatedly measuring the amount of the second infrared wavelength reflected from the blood, where the two infrared wavelengths are symmetrically disposed on different sides of the isobestic point.
- 60. Apparatus according to claim 38, 51 or 58 and wherein the light-emitting diodes emit light sequentially, and a central processing unit controls the apparatus.

10

15

20

- 61. Apparatus according to claim 38, 51 or 58 and wherein the red light is at about 660 nm and the infrared light is at about 830 nm, and a separate light-emitting diode provides light to the blood at about 810 nm.
- 62. Apparatus according to claim 39, 52 or 58 and wherein the red light is at about 660 nm and the infrared light is at about the isobestic point on the reflection curve of oxy- and deoxyhemoglobin.
- 63. Apparatus according to claim 39, 52 or 58 and wherein the providing fiber-optic cables are all equidistant from the receiving fiber-optic cable.
 - 64. Apparatus according to claim 48, 51 or 59 and wherein the software provides an approximation of the amount of light reflected at the isobestic point according to the following formula, where R equals the amount of reflected light:

$$R_{\text{ISOBESTIC}} = R_{\text{FIRST INFRARED}} + R_{\text{SECOND INFRARED}}$$

65. A method according to claim 48, 51 or 59 and wherein software provides an approximation of the amount of light reflected at the isobestic point according to the following formula, where R equals the amount of reflected light:

R_{ISOBESTIC} = R_{FIRST INFRARED} X R_{SECOND INFRARED}

15


66. Apparatus according to claim 38, 51 or 58 and wherein the software provides a calculation of hematocrit according to the following formula:

$$Hct = A \cdot R_{ISOBESTIC} + B \cdot R_{ISOBESTIC}^{2} + \frac{C}{R_{ISOBESTIC}} + \frac{D}{R_{ISOBESTIC}^{2}}$$

67. Apparatus according to claim 38, 51 or 58 and wherein the software provides a calculation of hematocrit according to the following formula where L and M are constants and $R_{\text{ISOBESTIC}}$ approximates the amount of light reflected from the blood at the isobestic wavelength:


$$Hct = Exp (L \cdot R_{ISORESTIC} + M/Ln(R_{ISORESTIC}^{2}))$$

68. Apparatus according to claim 39, 52 or 58 and wherein the providing fiber-optic cables are equidistant from the receiving fiber-optic cable.




SUBSTITUTE SHEET

2/21




SUBSTITUTE SHEET


3/21




SUBSTITUTE SHEET



SUBSTITUTE SHEET








FIG. 4A

SUBSTITUTE SHEET




FIG. 4C





FIG. 4D





SUBSTITUTE SHEET





FIG. 5D

WO 93/06775 PCT/US92/08396



11/21




FIG. 6B

WO 93/06775 PCT/US92/08396







FIG. 7A-I



SUBSTITUTE SHEET





SUBSTITUTE SHEET



16/21 s02 EQUATIONS PARTITIONING Exact & RATIO

DECISION POINT				
Hct RANGE	RATIO	EQN #	sO ₂ EQUATION	
	Rat≥R ₁	1	$A_1 \cdot Rat + \frac{B_1}{Rat} + C_1 \cdot (Rat^2) + D_1 \cdot Ln(Hct)$	
LEYEL	Rat≥R ₂	2	$\frac{A_2}{Rat} + \frac{B_2}{(Rat^2)} + C_2 \cdot Ln(Hct)$	
1	Rat≥R ₃	3	$A_3 \cdot Rat + \frac{B_3}{Rat} + \frac{C_3}{(Rat^2)} + D_3 \cdot Ln (Hct)$	
	Rat <r<sub>3</r<sub>	4	$A_4 \cdot Rat + \frac{B_4}{Rat} + \frac{C_4}{(Rat^2)} + D_4 \cdot Ln(Hct)$	
	Rat ≥R ₄	5	$A_5 \cdot Rat + \frac{B_5}{Rat} + \frac{C_5}{(Rat^2)} + D_5 \cdot Ln(Hct)$	
LEVEL 2	Rat≥R ₅	6	$A_6 \cdot Rat + \frac{B_6}{Rat} + \frac{C_6}{(Rat^2)} + Hct$	
	Rat≥R ₆	7	A ₇ ·Rat+ <mark>B₇ Rat</mark> +C ₇ ·Ln(Hct)+D ₇ · Hct Rat	
	Rat <r<sub>6</r<sub>	8	$A_8 \cdot Rat + \frac{B_8}{Rat} + \frac{C_8}{(Rat^2)} + D_8 \cdot Ln (Hct)$	
	Rat≥R ₇	9	$A_9 \cdot Rat + \frac{R_9}{Rat} + \frac{C_9}{(Rat^2)} + D_9 \cdot \frac{Rat}{Hct}$	
LEVEL 3	Rat≥R ₈	10	$A_{10} \cdot Rat + \frac{B_{10}}{Rat} + \frac{C_{10}}{(Rat^2)} + D_{10} \cdot Ln(Hct) + E_{10} \cdot \frac{Hct}{Rat}$	
	Rat ≥R ₉	11	$A_{11} \cdot Rat + \frac{B_{11}}{Rat} + C_{11} \cdot Ln (Hct) + D_{11} \cdot \frac{Hct}{Rat}$	
	Rat < Rg	12	$A_{12} \cdot Rat + \frac{B_{12}}{Rat} + \frac{C_{12}}{(Rat^2)} + D_{12} \cdot Ln(Hct)$	
	Rat≥R ₁₀	13	$A_{13} \cdot Rat + \frac{B_{13}}{Rat} + \frac{C_{13}}{(Rat^2)} + D_{13} \cdot \frac{Rat}{Hct}$	
I FVFI	Rat≥R ₁₁	14	$A_{14} \cdot Rat + \frac{B_{14}}{Rat} + \frac{C_{14}}{(Rat^2)} + \frac{D_{14}}{Hct}$	
LEYEL 4	Rat≥R ₁₂	15	A ₁₅ ·Rat+ ^B ₁₅ +C ₁₅ ·Ln(Hct)+D ₁₅ · <u>Hct</u>	
	Rat < R ₁₂	16	$\frac{A_{16}}{Rat} + \frac{B_{16}}{(Rat^2)} + C16 \cdot Ln(Hct)$	

WHERE:
Rat=RATIO IR/RED $A_i - E_i = COEFFICIENTS$

Hct=CALCULATED HEMATOCRIT

Hct LEVELS: 1=HIGHEST TO 4=LOWEST RANGE FIG. 8A

 ${
m s0}_2$ EQUATIONS PARTITIONING BY Hct

-		
DECISION POINT	EQN #	sO ₂ EQUATION
r = 0	н	$A_1 \cdot Rat + \frac{B_1}{Rat} + \frac{C_1}{(Rat^2)} + D_1 \cdot Rct + \frac{E_1}{Hct} + \frac{E_1}{Hct^2}$
	2	A ₂ ·Rat+Rat + C ₂ +D ₂ ·Rat+Rct+ C ₂ + C ₂
	3	A3. Rat + B3 + C3 + D3. Rat + E3 + E3 + 63 Hct
	ф	A4 · Rat + Rat + C4 + D4 · Rat + F4 + F4 + Hct

WHERE: Rat=RATIO IR/RED A₁-G₁=COEFFICIENTS

Hct=CALCULATED HEMATOCRIT
Hct LEVELS: 1=HIGHEST TO 4=LOWEST RANGE

FIG. 8B





FIG. 8C-I



SUBSTITUTE SHEET

20/21 YES EGN .. 0N YES EQN 2 9 YES EQN 3 FIG. 8D 9 EQN 4

SUBSTITUTE SHEET




FIG. 9

International Application No

I. CLASSIF	TCATION OF SUP	MATTER (if several classification sym	abols apply, indicate all)6	
_	to International P	ossification (IPC) or to both National Class G01N21/31	ssification and IPC	
D. FIELDS	SEARCHED			
		Minimum Document	tation Searched?	
Classificati	ion System	a	lassification Symbols	
Int.Cl.		A61B ; G01N		·
		Documentation Searched other th to the Extent that such Documents are		
III. DOCUM		ED TO BE RELEVANT ⁹		
Category °	Citation of De	ocument, 11 with indication, where appropriate	e, of the relevant passages 12	Relevant to Claim No.13
X	11 Octo	776 340 (B. L. MORAN ET ber 1988 n the application	AL.)	1-3, 13-16, 22,24, 34-38,60
Y	see col	umn 7, line 59 - line 66	,	6,8-10, 12,25, 43,45, 46,50,
A	see col	umn 8, line 27 - line 40	· .	54,55 5,20,21, 23,41, 42, 47-49, 51,56, 57,61, 62,66
	see colu 26; cla	umn 17, line 3 - column ims	18, line	4. , 5.
		· · · · · · · · · · · · · · · · · · ·	-	
° Special	l categories of cited do	cuments: 10	To later document published after the Internal	tional filing date
CDE	ssidered to be of partic		or priority date and not in conflict with the cited to understand the principle or theory invention "X" document of particular relevance; the claim	underlying the
filir "L" doc	ng date ument which may thro	w doubts on priority claim(s) or	cannot be considered novel or cannot be of involve an inventive step	onsidered to
cita: "O" doc	tion or other special re sument referring to an	the publication date of another eason (as specified) oral disclosure, use, exhibition or	"Y" document of particular relevance; the clair cannot be considered to involve an inventi- document is combined with one or more of ments, such combination being obvious to	ve step when the ther such docu-
"P" doc	er means ument published prior er than the priority date	to the international filing date but e claimed	in the art. "&" document member of the same patent fami	
IV. CERTI	FICATION			
Date of the	Actual Completion of t	the International Search	Date of Mailing of this International Searce	th Report
	19 JANUA	ARY 1993	< 02.02.93	
Internationa	Searching Authority		Signature of Authorized Officer	
	EUROPE/	AN PATENT OFFICE	FONTENAY P.H.	

Tategory Of Citation of Discouration, where appropriate, of the relevant passage Y US,A,4 651 741 (PASSAFARO) 12,25, 24 March 1987 43,45, 46,50, 54,55 5,13,14, 22-24, 34-38, 41,42, 51,57, 61,62 Y US,A,5 048 524 (W. H. BAILEY) 17 September 1991 41,42 A see abstract 18,10, 13-16, 22,23, 39,45, 51,52, 54,55, 57,58 A see column 2, line 52 - column 3, line 30 see column 8, line 13 - line 33 see column 9, line 4 - line 66; figures 1-5 Y EP,A,0 380 664 (TERUMO K. K.) 1-3, 34-38, 41,42 1-3, 34-38,	III. DOCUME	HE RELEVANT (CONTINUED FROM THE SECOND S	Relevant to Claim No.
Y US, A, 4 561 74 (PASSAFARO) 24 March 1987 cited in the application A see the whole document Y US, A, 5 048 524 (W. H. BAILEY) 17 September 1991 A see abstract A see column 2, line 52 - column 3, line 30 see column 8, line 13 - line 33 see column 9, line 4 - line 66; figures 1-5 Y EP, A, 0 380 664 (TERUMO K. K.) 8 August 1990 A see page 2, line 23 - page 5, line 3 A WO, A, 9 007 905 (FUTREX INC.) 26 July 1990 see page 14, line 26 - page 15, line 18; figure 6 A US, A, 4 745 279 (M. N. KARKAR ET AL.) 17 May 1988 cited in the application See abstract; claims 12, 25, 43, 45, 51, 51, 52, 51, 52, 51, 52, 51, 52, 51, 52, 51, 52, 51, 52, 51, 52, 51, 52, 51, 52, 51, 54, 51, 54, 57, 60-62 See bage 14, line 26 - page 15, line 18; figure 6 A US, A, 4 745 279 (M. N. KARKAR ET AL.) 17 May 1988 cited in the application See abstract; claims		Citation or Document, with indication, where appropriate, of the relevant passage	
Y US,A,5 048 524 (W. H. BALLET) 17 September 1991 A see abstract See abstract See column 2, line 52 - column 3, line 30 See column 8, line 13 - line 33 See column 9, line 4 - line 66; figures 1-5 Y EP,A,O 380 664 (TERUMO K. K.) 8 August 1990 A see page 27, line 23 - page 5, line 3 See page 27, line 4 - line 16 See page 32, line 10 - page 35, line 23 A WO,A,9 007 905 (FUTREX INC.) 26 July 1990 See page 14, line 26 - page 15, line 18; figure 6 A US,A,4 745 279 (M. N. KARKAR ET AL.) 17 May 1988 Cited in the application See abstract; claims 34-38, 41,42 22,23,45, 51,54, 57,60-62 4,11,17, 40,52,59		24 March 1987 cited in the application	12,25, 43,45, 46,50, 54,55 5,13,14, 22-24, 34-38, 41,42, 51,57,
A see abstract A see column 2, line 52 - column 3, line 30 see column 8, line 13 - line 33 see column 9, line 4 - line 66; figures 1-5 Y EP,A,0 380 664 (TERUMO K. K.) 8 August 1990 A see page 2, line 23 - page 5, line 3 A wo,A,9 007 905 (FUTREX INC.) 26 July 1990 see page 14, line 26 - page 15, line 18; figure 6 A US,A,4 745 279 (M. N. KARKAR ET AL.) 17 May 1988 cited in the application 13-16, 22,23, 39,45, 51,52, 57,58 60-62 1-3, 34-30, 34-38, 41,42 1-3, 34-38, 41,42 10,13, 14,22, 23,45, 51,54, 57,60-62 4,11,17, 40,52,59 1,8,14, 15, 34-39, 45, 47-49, 51,52, 55,57,62	Y	US,A,5 048 524 (W. H. BAILEY) 17 September 1991	34-38,
See Column 8, line 13 - line 33 see column 9, line 4 - line 66; figures 1-5 Y EP,A,O 380 664 (TERUMO K. K.) 8 August 1990 A see page 2, line 23 - page 5, line 3 See page 27, line 4 - line 16 see page 32, line 10 - page 35, line 23 A WO,A,9 007 905 (FUTREX INC.) 26 July 1990 see page 14, line 26 - page 15, line 18; figure 6 A US,A,4 745 279 (M. N. KARKAR ET AL.) 17 May 1988 cited in the application 1.8,14, 15, 34-39, 45, 47-49, 51,52, 55,57,62	Α .		13-16, 22,23, 39,45, 51,52, 54,55,
A see page 27, line 23 - page 5, line 3 A WO,A,9 007 905 (FUTREX INC.) 26 July 1990 see page 14, line 26 - page 15, line 18; figure 6 A US,A,4 745 279 (M. N. KARKAR ET AL.) 17 May 1988 cited in the application 34-38, 41,42 10,13, 14,22, 23,45, 51,54, 57,60-62 4,11,17, 40,52,59 1,8,14, 15, 34-39, 45, 47-49, 51,52, 55,57,62	Α .	see column 8, line 13 - line 33 see column 9, line 4 - line 66; figures	60-62
A see page 2, Time 23 - page 3, Time 5 see page 27, line 4 - line 16 see page 32, line 10 - page 35, line 23 WO,A,9 007 905 (FUTREX INC.) 26 July 1990 see page 14, line 26 - page 15, line 18; figure 6 A US,A,4 745 279 (M. N. KARKAR ET AL.) 17 May 1988 cited in the application 14,22, 23,45, 51,54, 57,60-62 4,11,17, 40,52,59 1,8,14, 15, 34-39, 45, 47-49, 51,52, 55,57,62	Y	EP,A,O 380 664 (TERUMO K. K.) 8 August 1990	34-38, 41,42
See page 32, line 10 - page 35, line 23 WO,A,9 007 905 (FUTREX INC.) 26 July 1990 see page 14, line 26 - page 15, line 18; figure 6 US,A,4 745 279 (M. N. KARKAR ET AL.) 17 May 1988 cited in the application 1,8,14, 15, 34-39, 45, 47-49, 51,52, 55,57,62	A	see page 2, line 23 - page 5, line 3	14,22, 23,45, 51,54,
A		see page 27, line 4 - line 16 see page 32, line 10 - page 35, line 23	
15, 34-39, 45, 47-49, 51,52, 55,57,62	A	26 July 1990 see page 14, line 26 - page 15, line 18;	
	A	17 May 1988	15, 34-39, 45, 47-49, 51,52,

III. DOCUM	ENTS CONSIDE TO BE RELEVANT (CONTINUED FROM THE SECOND SECTION	
Category °	Cital Document, with indication, where appropriate, of the relevant passa	Relevant to Claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 15, no. 140 (P-1188)9 April 1991 & JP,A,30 18 742 (TERUMO CORP) see abstract	
P,X	US,A,5 066 859 (M. N. KARKAR ET AL.) 19 November 1991	1-3, 34-39, 60,62, 63,68
P,A	see abstract	8,10,13, 14,22, 23,41, 45,51, 52,54, 55,57
P,A	see column 2, line 34 - column 3, line 28 see column 6, line 47 - column 7, line 5 see column 13, line 42 - line 55; claim 25; figures	55,57
		·
		4
		·

9208396 US SA 65968

This armex firsts the patent family members relating to the patent documents cited in the above-mentioned international search report.

The members are as contained in the European Patent Office EDP file on

The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19/0 19/01/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
US-A-4776340	11-10-88	EP-A- JP-A-	0285307 63283627	05-10-88 21-11-88	
US-A-4651741	24-03-87	CA-A- EP-A,B JP-B- JP-T- WO-A-	1268347 0224571 3026975 62503018 8606946	01-05-90 10-06-87 12-04-91 03-12-87 04-12-86	
US-A-5048524	17-09-91	None			
EP-A-0380664	08-08-90	JP-A- JP-A- WO-A- US-A-	1029738 1029739 8901144 5149503	31-01-89 31-01-89 09-02-89 22-09-92	
WO-A-9007905	26-07-90	US-A- AU-A- EP-A- JP-A- US-A- US-A-	5028787 5042190 0456716 2191434 5086229 5068536	02-07-91 13-08-90 21-11-91 27-07-90 04-02-92 26-11-91	
us-a-4745279	17-05-88	CA-A- EP-A- JP-A-	1279499 0231652 62265563	29-01-91 12-08-87 18-11-87	
US-A-5066859	19-11-91	None			